Neurovascular Innovation

Diverting Flow.
Transforming
Outcomes.

ThruFlo Endovascular is developing a first-in-class dual-limb bifurcation aneurysm flow diverter for the treatment of complex intracranial aneurysms at arterial branch points.

~6.5M
People affected in US
$3.8B
Global market by 2026
First-in-Class Device

Dual-Limb Flow Diverter

Designed from the ground up for bifurcation aneurysms — the indication that existing flow diverters cannot adequately treat.

Who We Are

Built Around an Unmet Need

ThruFlo Endovascular is a clinical-stage medical device company focused on endovascular solutions for life-threatening neurovascular conditions. We are headquartered in Southern California and supported by a world-class team of engineers, clinicians, and advisors.

01

Vision

To become the global leader in endovascular treatment of complex intracranial aneurysms, starting with the bifurcation indication that affects millions and lacks adequate solutions.

02

Mission

To develop and commercialize next-generation flow diversion technology that expands the addressable patient population and improves outcomes for those at risk of life-threatening aneurysm rupture.

03

Strategy

Pioneer the bifurcation flow diverter category, build a proprietary IP portfolio, generate pre-clinical and clinical evidence, and position the company as a strategic acquisition target for leading medtech consolidators.

The Unmet Need

A Gap Current Devices Cannot Fill

Intracranial aneurysms are a serious and common condition. Bifurcation aneurysms — occurring at arterial branch points — represent a large portion of cases (50-60%) and are poorly served by existing endovascular devices.

~6.5M

Americans living with an unruptured intracranial aneurysm

30–40%

Of patients die within 30 days of rupture; survivors often face permanent disability

Existing flow diverters are designed for side-wall aneurysms along straight arterial segments. Bifurcation aneurysms — located at branch points — require a fundamentally different device architecture. ThruFlo's dual-limb design was built specifically to address this gap.

The Device

A Category-Defining Flow Diverter

The ThruFlo flow diverter features a proprietary dual-limb design that deploys across the bifurcation, redirecting blood flow away from the aneurysm sac while preserving access to both daughter vessels.

01

Dual-Limb Architecture

Proprietary bifurcated stent design spans the aneurysm neck and extends into both daughter vessels — the only configuration that can adequately treat bifurcation anatomy.

02

Flow Diversion Mechanism

High-density mesh redirects blood away from the aneurysm dome, promoting progressive thrombosis and eventual occlusion while maintaining normal vessel perfusion.

03

Endovascular Delivery

Catheter-based deployment using standard guide wires and guiding catheters used in the neurovascular arena, consistent with the minimally invasive standard of care.

04

Pre-clinical Validation

Animal studies confirm successful deployment and 2 month device patency providing foundational evidence for the clinical program.

05

Designed for the Indication

Unlike side-wall flow diverters or balloon assisted coiling, which is currently used off label by physicians, ThruFlo's device was designed from the ground up for bifurcation aneurysms.

06

Proprietary IP Portfolio

ThruFlo has created a formidable intellectual property anchoring multiple issued and pending US and international patents.

Formidable IP Position

ThruFlo has created a formidable intellectual property anchoring multiple issued and pending US and international patents, establishing strong barriers to entry across the bifurcation flow diverter category.

Why ThruFlo

Advantages of the ThruFlo Device

The ThruFlo bifurcation flow diverter was purpose-built for an indication that existing devices cannot adequately address. Its design delivers meaningful clinical and economic advantages over current treatment options.

01

Single Modality Device

The ThruFlo flow diverter is designed to be used as a single device placed adjacent to the aneurysm sack, redirecting flow away from the aneurysm without additional adjunctive devices.

02

Proven Technology

The device architecture is built upon the proven technology of established flow diverters but now adopted and purpose-engineered for the unique demands of the bifurcation indication.

03

Shorter Procedure

Because the device functions as a single modality for bifurcation aneurysms, the procedure is simpler and significantly shorter than multi-device approaches currently used off-label.

04

Avoids Aneurysm Sack

The procedure does not require catheterization of the aneurysm sack, eliminating a key step that carries risk of perforation and procedural complication.

05

No Coiling Required

Unlike coiling-based approaches, the ThruFlo device does not require catheterization of the aneurysm sack, directly reducing procedural risk to the patient.

06

Lower Cost

As a single modality device, both device cost and procedure time are reduced — making ThruFlo a more economically efficient solution for patients and providers.

07

Health Insurance Coverage Pathway

Flow diverters already have FDA approval and established DRG codes. Because of ThruFlo's reduced cost profile and compatibility with existing codes, establishing DRG reimbursement will be straightforward — reducing commercialization risk.

Leadership

Board of Directors

ThruFlo is guided by experienced operators, clinicians, and investors with deep medtech expertise across device development, interventional procedures, and strategic finance.

Samuel Shaolian

Samuel Shaolian

Chief Executive Officer & Co-Founder

Samuel M. Shaolian has more than 40 years of experience in the design, development and management of biomedical devices and companies. Prior to joining ThruFlo as its co-founder and CEO, Mr. Shaolian was co-founder and board member of multiple medtech companies including: Vascular Medcure (catheter-based minimally invasive thrombectomy and embolectomy devices, acquired by Medtronic 2021), ValCare Medical (minimally invasive mitral valve repair), MiCardia Corporation (dynamically activated annuloplasty rings for mitral valve regurgitation), Elipse Medical (dynamically activated implants for orthopedic disorders, acquired by Nuvasive), Onset Medical (expandable sheath systems for structural heart procedures, acquired by TRUMO), and Vertelink Corporation (minimally invasive systems for spine disorders, acquired by Medtronic). He is inventor or co-inventor of over 90 issued and pending patents. Mr. Shaolian holds a BSc in Mechanical Engineering and an MSc in Biomedical Engineering from Tel Aviv University, Israel.

George Teitelbaum

George Teitelbaum, MD, FSIR

Chief Medical Officer & Co-Founder

George Teitelbaum, MD, FSIR is a board-certified interventional radiologist and interventional neuroradiologist with more than 38 years of endovascular procedure experience. He graduated from UCLA with a B.S. in biochemistry and earned his M.D. from UC San Diego. He is a Fellow at the Society of Interventional Radiology. Dr. Teitelbaum completed fellowships in Interventional Radiology (George Washington University Hospital), Magnetic Resonance Imaging (Huntington Medical Research Institute), Interventional Neuroradiology (UC San Francisco), and Prostate Embolization (San Jose Hospital, Lisbon). He has served on the medical faculties of Thomas Jefferson University, Georgetown University, Keck/USC School of Medicine, and Children’s Hospital Los Angeles (CHLA). He currently serves as Professor of Radiology at USC/Keck School of Medicine. He is the author/co-author of more than 100 peer-reviewed scientific journal articles and holds multiple U.S. and international patents for medical device inventions. At USC/Keck School of Medicine, he has performed among the largest series of endovascular operations in Southern California for acute strokes, cerebral aneurysms, and brain and spinal vascular malformations, and in 2015 introduced prostate embolization to the Los Angeles area.

Peter Qi

Peter Qi

Director

Peter Qi is a finance and investment professional with deep experience supporting emerging growth companies in healthcare and medtech. As a Director of ThruFlo, he provides strategic oversight across finance, fundraising, governance, and corporate development. A CPA with prior experience at PricewaterhouseCoopers and KPMG, Peter has advised companies on financial strategy, corporate transactions, and regulatory compliance. His expertise spans venture investing, corporate finance, and international business operations. He represents Atlas MedInnovation on ThruFlo’s board and is committed to helping transformative technologies create lasting impact in healthcare.

Scientific Advisory Board

Clinical & Scientific Leadership

ThruFlo's Scientific Advisory Board brings together leading neurological surgeons and interventional neuroradiologists who provide clinical guidance and scientific direction to accelerate the company's development program.

George Teitelbaum
USC / Keck School of Medicine

George Teitelbaum, MD, FSIR

Interventional Neuroradiologist with 38+ years of endovascular experience. Co-Founder of ThruFlo Endovascular and Director of Interventional Neuroradiology at USC/Keck School of Medicine.

William Mack
USC / Keck School of Medicine

William Mack, MD

William Mack, MD is Professor of Neurological Surgery and Director of Neurointerventional Surgery at USC/Keck School of Medicine, Los Angeles, CA. He is the author or co-author of more than 300 scientific articles. Dr. Mack’s major areas of clinical interest are stroke, brain aneurysms, subarachnoid hemorrhage, arteriovenous malformations (AVMs), arteriovenous fistulas, cavernous malformations, carotid artery disease, intracranial stenosis, and brain tumors. He performs both open surgery and minimally invasive endovascular procedures for cerebrovascular disorders.

Dr. Mack is a faculty member of the Neuroscience Graduate Program and Principal Investigator and Director of the Cerebrovascular Laboratory in the Zilkha Neurogenetic Institute. He receives NIH R01 funding for his laboratory research. His scientific interests focus on translational efforts to treat ischemic and hemorrhagic stroke, with laboratory investigations concentrating on the pathophysiology of cerebral ischemia and inflammatory modulation.

Dr. Mack received his Bachelor’s degree with honors from Cornell University, then attended Columbia University College of Physicians and Surgeons, where he graduated from medical school (Alpha Omega Alpha) and completed Neurosurgical residency training. During residency he completed a post-doctoral cerebrovascular research fellowship at Columbia University. Following residency, he completed an Interventional Neuroradiology/Neuroendovascular Surgery fellowship at UCLA.

Dr. Mack is board certified by the American Board of Neurological Surgery (FAANS) and is a Fellow of the American Heart Association (FAHA). He serves on the executive council of the CNS/AANS Cerebrovascular Section, as Associate Editor of the Journal of Neurointerventional Surgery, and on the editorial board of World Neurosurgery.

Headquarters

Our Location

ThruFlo Endovascular is headquartered in Irvine, California, in the heart of Southern California’s medtech corridor.

Address
470 Wald
Irvine, CA 92618
United States
Get Directions  →
Alton Pkwy Barranca Pkwy Wald Jeronimo 470 Wald Irvine, CA 92618 N Open in Google Maps →
Press

Latest News

FOR IMMEDIATE RELEASE
ThruFlo Endovascular Secures Seed Funding to Advance First Purpose-Built Flow Diverter for Bifurcation Aneurysms

IRVINE, Calif. — ThruFlo Endovascular, Inc., a neuro-endovascular medical device company, today announced the completion of seed funding led by Atlas MedInnovation (Irvine, CA) to accelerate development of its novel bifurcated flow diverter platform. Proceeds will be used to establish formal R&D operations, complete device design, initiate additional pre-clinical studies, and submit an Investigational Device Exemption (IDE) application to the FDA.

Cerebral aneurysms affect an estimated 16.5 million Americans. Approximately 60% of intracranial aneurysms occur at the branch points of major vessels, where standard flow diverters were never designed to work. ThruFlo’s device addresses this gap with an anatomically specific, dual-limb Y-shaped design that deploys as a single modality, eliminating the need for coiling and reducing procedural complexity, time, and risk.

“Today’s interventionalists are using sidewall off-label devices such as stents with multiple detachable coils or intrasaccular devices for treatment of bifurcation aneurysms, because there is simply nothing better available,” said Samuel M. Shaolian, CEO of ThruFlo Endovascular. “Our device was designed from the ground up for this indication. Pre-clinical studies confirmed successful deployment and two-month device patency, and we are focused on building the evidence that translates into better outcomes for patients.”

ThruFlo holds a strong IP portfolio anchored by multiple issued and international patents and additional US and international pending patent applications. The company is supported by a Scientific Advisory Board that includes leading neurological surgeons and interventional neuroradiologists from USC/Keck School of Medicine.

The global neurovascular device market is a growing multi-billion-dollar category projected to reach USD 3.8 billion by 2026, attracting significant acquisition interest from Johnson & Johnson, Medtronic, and Stryker.

“ThruFlo represents exactly the kind of innovation we built Atlas MedInnovation to support—a clear unmet clinical need, strong intellectual property, and a team with deep domain expertise,” said Peter S Qi, Director of lead investor Atlas MedInnovation. “Bifurcation aneurysms have long been underserved by existing devices, and ThruFlo’s purpose-built approach has the potential to meaningfully improve patient outcomes. We are proud to provide the funding, facility, and industry resources to help accelerate this technology from concept to clinic.”

About Atlas MedInnovation

Atlas MedInnovation is a Southern California–based medical device incubator and foundry that transforms innovative ideas and intellectual property into commercially viable medical devices. Atlas partners with physicians, professors, researchers, engineers, and entrepreneurs—providing end-to-end incubation support from concept through product development to commercial launch. Operating out of a 6,000+ square-foot Class A facility in Orange County with dedicated lab space and private offices, Atlas offers seed funding, hands-on operational and management guidance, and deep industry resources, including access to an extensive network of biomedical and mechanical engineers, medtech product development professionals, and more than 48 hospitals and 100 device ODMs/CDMOs in the region. Atlas’s portfolio spans a range of interventional technologies, including micro, guide, and access catheters, embolization coils, and cryoablation systems. For more information, visit www.atlasmedinnovation.com.

Media Contact
ThruFlo Endovascular, Inc.
info@thrufloendovascular.com